were then crossed over to the opposite therapy.
Patients and methods
Patients selected for this prospective study attended the glaucoma clinic of the University Department of Ophthalmology, AHEP A Hospital, Thessaloniki, Greece between June 1997 and June 1998. We included in this investigation all exfoliation glaucoma patients of either sex who were: (i) older than 50 years of age, (ii) required a lower intraocular pressure to prevent glaucomatous progression despite combination therapy of timolol and dorzolamide and (iii) demonstrated on these medicines an intraocular pressure �20 mmHg at at least one timepoint during the baseline 24 hour period. Moreover, patients must have demonstrated a typical glaucomatous visual field loss (nasal step, or arcuate, paracentral or Seidel's scotoma) as determined by automated static threshold perimetry (Octopus 500 EZ, Gl programme, Zurich) and glaucomatous optic nerve head cupping (neural rim notching or saucerisation).
Patients were excluded from this study if they demonstrated a history of ocular surgery/trauma, previous use of steroids, contact lens use, dry eyes, corneal abnormality, or any condition that prevented reliable applanation tonometry. Also excluded were patients with: evidence of ocular infection, inflammation or history of renal or hepatic impairment or moderate to severe cataract. In patients with bilateral exfoliation glaucoma one eye was randomly selected to be included in this study.
Thirty-five consecutive Greek patients with exfoliation glaucoma were enrolled of whom 30 completed the study. Of the patients who failed to complete, 1 discontinued due to the inconvenience of hospitalisation, 1 patient could not obtain latanoprost drops from his medical insurance doctor; and 3 patients withdrew due to ocular allergy to either pilocarpine or latanoprost drops. Of the 30 patients included in this study, 22 had undergone the baseline 24 hour curve (timolol and dorzolamide treated curve) previously as part of another study?
The methods for the present study were similar to those described previously. Subsequently all exfoliation glaucoma patients were randomised in a crossover fashion to treatment with latanoprost 0.005% or pilocarpine 4%. 
Statistics
Statistical analyses for intraocular pressure for intra-and inter-group analyses were performed using a paired t test.8 An F-test was used to evaluate differences in the standard deviations between the different treatments at each timepoint.8 The significance level was set at 5% and a two-way analysis was used for all tests. This study had an 80% power to exclude a 1.0 mmHg difference assuming a standard deviation of 1.8 mmHg between treatment periods.9,lD Adverse events were evaluated by a McNemar testY
Results

Patients
Seventeen men and 13 women (30 patients) with exfoliation glaucoma completed this study who had a mean age of 68.1 years (range 54-76 years). All patients were white. The mean baseline parameters of these 30 patients were mean visual acuity 0.7 (SD ± 0.3), mean vertical cup-to-disc ratio 0.7 (SD ± 0.1) and mean deviation of 13.3 dB (SD ± 5.8) on visual field testing.
Intraocular pressure
The baseline intraocular pressures (treated values with timolol and dorzolamide twice daily) and treatment period pressures are shown in Table 1 . Differences frong baseline and between treatments are shown in Table 2 .
Compared with baseline measurements both latanoprosi and pilocarpine caused a significant reduction in intraocular pressure at each timepoint throughout the 24 hour period.
Latanoprost caused a greater reduction than pilocarpine from baseline at the 06:00 and 10:00 timepoints. However, pilocarpine caused a lower pressure at 22:00 hours and demonstrated a diurnal Regarding the distribution of intraocular pressure as indicated by the standard deviation, no differences between pilocarpine and latanoprost were noted at any timepoint or the diurnal average. Although patients complied for the duration of the study the majority found compliance far more difficult with pilocarpine.
Adverse events
Of the 5 patients who discontinued the study early, 3 (9%) did so due to an adverse event (ocular allergy). Two (6%) of these were during pilocarpine treatment and one (3%) during latanoprost treatment.
Of the 30 patients completing the study, 3 (10%)
complained of blurred vision with pilocarpine. This side effect was not observed with latanoprost. One patient experienced browache and headache with pilocarpine (3%). One patient (3%) complained of dizziness with latanoprost. These side-effects did not affect the investigation but resulted in discontinuation of the medications after the end of the study period. In addition,S patients (17%) in the latanoprost arm and 4 (13%) in the pilocarpine arm experienced stinging and 'dry eye sensation' thought to be associated with punctate epitheliopathy. Finally, 2 patients (7%) on pilocarpine and one patient (3%) on latanoprost In the present study we evaluated the efficacy and safety of pilocarpine 4% given four times daily compared with latanoprost 0.005% given every evening as third line therapy to dorzolamide 2% and timolol maleate 0.5% solution both given twice daily. This study showed that both pilocarpine and latanoprost caused a significant reduction in intraocular pressure from baseline (dorzolamide and timolol therapy) at each measured timepoint over 24 hours. When treatment periods were compared, the mean diurnal pressures (mean of six measurements over a 24 hour period) on latanoprost and pilocarpine were statistically equal, although there was a trend towards greater diurnal efficacy of latanoprost. In addition, the mean peak intraocular pressure for each patient was equal between groups. Latanoprost, however, was more effective statistically in reducing the intraocular pressure than pilocarpine in the morning hours (6:00, 10:00 hours). In contrast, pilocarpine was more effective at 22,00 hours than latanoprost.
The fact that latanoprost did not statistically lower the diurnal intraocular pressure more than pilocarpine in our study was a surprise to the authors. The reasons for the similar efficacy could not be completely explained but may include the fact that since the exfoliation glaucoma patients were already being treated with two 
